Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC11A2 | P49281 | 1/20 | 0.68 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | IDO1 | P14902 | 10/20 | 0.50 |
| ▸ | NOS1 | P29475 | 3/20 | 0.48 |
| ▸ | ATP1A1 | P05023 | 1/20 | 0.44 |
| ▸ | ATP1B1 | P05026 | 1/20 | 0.44 |
| ▸ | ATP1A3 | P13637 | 1/20 | 0.44 |
| ▸ | ATP1B2 | P14415 | 1/20 | 0.44 |
| ▸ | ATP1A2 | P50993 | 1/20 | 0.44 |
| ▸ | ATP1B3 | P54709 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4008750 | 0.98 | SLC11A2 (0.66) | SLC11A2TP53CYP3A4SMN1; SMN2CYP1A2 | |
| SCHEMBL13007575 | 0.98 | SLC11A2 (0.64) | SLC11A2TP53CYP3A4SMN1; SMN2CYP1A2 | |
| SCHEMBL2807819 | 0.95 | SLC11A2 (0.73) | SLC11A2TP53CYP3A4SMN1; SMN2CYP1A2 | |
| Bromide SCHEMBL2810291 | 0.93 | SLC11A2 (0.70) | SLC11A2TP53CYP3A4SMN1; SMN2CYP1A2 | |
| SCHEMBL3690053 | 0.93 | SLC11A2 (0.64) | SLC11A2TP53CYP3A4SMN1; SMN2CYP1A2 | |
| Bromide SCHEMBL4008068 | 0.91 | SLC11A2 (0.62) | SLC11A2TP53CYP3A4SMN1; SMN2CYP1A2 | |
| SCHEMBL3687900 | 0.87 | SLC11A2 (0.63) | SLC11A2TP53CYP3A4SMN1; SMN2CYP1A2 | |
| Hydrochloric Acid SCHEMBL2811607 | 0.85 | SLC11A2 (0.61) | SLC11A2TP53CYP3A4SMN1; SMN2CYP1A2 | |
| SCHEMBL3688145 | 0.81 | SLC11A2 (0.61) | SLC11A2TP53CYP3A4SMN1; SMN2CYP1A2 | |
| SCHEMBL3688121 | 0.81 | SLC11A2 (1.00) | SLC11A2TP53CYP3A4SMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010005851-A1 | COMBINATION THERAPY FOR TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2010-01-14 | — | — | WO | claimed |
| EP-2068855-A2 | AROMATIC AND HETEROAROMATIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2009-06-17 | — | — | EP | claimed |
| WO-2008151288-A2 | AROMATIC AND HETEROAROMATIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2008-12-11 | — | — | WO | claimed |
| US-20100240713-A1 | AROMATIC AND HETEROAROMATIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2010-09-23 | — | — | US | disclosed |
| US-20100240713-A1 | AROMATIC AND HETEROAROMATIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2010-09-23 | — | — | US | disclosed |
| WO-2010005851-A1 | COMBINATION THERAPY FOR TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2010-01-14 | — | — | WO | disclosed |
| EP-2068855-A2 | AROMATIC AND HETEROAROMATIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008151288-A2 | AROMATIC AND HETEROAROMATIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008151288-A2 | AROMATIC AND HETEROAROMATIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240713-A1 | AROMATIC AND HETEROAROMATIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | SLC40A1, PAH, FECH | SLC11A2 175/4885TP53 1837/4885CYP3A4 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.